Pain Category Archives — DC Medical Malpractice & Patient Safety Blog Published by Washington, D.C. Personal Injury Lawyers

May 4, 2021

U.S. ends confusion and expands prescribing of opioid-fighting medication

Health workers with legal prescribing privileges have gotten newly revised federal guidelines — once again — making it easier for them to help those addicted to powerful opioid painkillers by prescribing buprenorphine, another powerful medication.

This action could be beneficial in battling the opioid abuse and drug overdose crisis that ebbed in recent times and then worsened during the coronavirus pandemic, overall killing hundreds of thousands of Americans.

As the Washington Post reported of regulators’ latest decisions:

March 24, 2021

Plutocratic clan offers $1 billion more in bankruptcy bid to end opioid suits

by Patrick A. Malone

Members of the plutocratic Sackler clan have upped the ante yet again in a bankruptcy court bid to settle thousands of lawsuits targeting Purdue Pharmaceutical, the company long in the family’s grip and blamed for untold misery in the now-resurgent opioid abuse and drug overdose crisis.

The latest, and perhaps final plan submitted to the courts for approval would oust the family from Purdue, converting it into a public trust company.

The Sacklers say they will add a billion dollars more from the family’s formidable fortunes to sums that would be extracted from the company itself.

March 10, 2021

Is killer opioid crisis an ‘afterthought,’ as U.S. struggles with many problems?

by Patrick A. Malone

Although the Biden Administration may be winning Americans’ approval for its battle against the coronavirus pandemic, drug abuse experts have expressed rising worry that federal efforts are lagging in the fight against a rising health menace: the resurgent opioid abuse and drug overdose crisis.

While overdoses for the first time might claim 100,000 U.S. lives in a single year, the national campaign to quell the opioid crisis, a top priority not that long ago, has become almost an “afterthought” for policy makers in Washington, D.C., the medical news site Stat reported:

“According to interviews with leading doctors, lobbyists, members of Congress, and multiple Biden Administration aides, proposed reforms include billions of new dollars for treatment and recovery services, a deregulation of addiction treatment medications, making many of 2020’s emergency telehealth allowances permanent, and scaling up harm-reduction offerings like needle exchanges, fentanyl test strips, and naloxone [an overdose antidote] distribution. But over a month into Biden’s presidency, it’s not clear when, or even if, a major push on addiction treatment will happen. Even if one does, it’s an open question whether it will lead to modest changes or the more radical approach some advocates say the crisis deserves.”

February 17, 2021

Big Pharma’s twist: Billions in opioid settlements convert into huge tax breaks

by Patrick A. Malone

While too many Americans struggle with skyrocketing prescription drug costs, so much so that a $10 insurance co-payment may be lethally dissuasive, Big Pharma firms are seeking billions of dollars in taxpayer-funded benefits on giant settlements they made for their role in the opioid abuse and drug overdose crisis.

Johnson & Johnson and the “big three” distributors of prescription drugs — McKesson, AmerisourceBergen and Cardinal Health — have disclosed that they will take tax deductions on sums they will fork over to states, local governments, Indian tribes, and others that sued them over damages that they say occurred after they flooded the country with powerful painkillers, the Washington Post reported.

The four companies have agreed to pay between $5 billion and $8 billion each to reimburse communities for the costs they suffered in dealing with millions of deaths, addictions, and debilitations caused by opioids, their synthetic versions, and illicit drugs they opened the door to.

February 10, 2021

Consultant to pay $573.9 million as consequence of its sketchy opioid advice

by Patrick A. Malone

The opioid abuse and drug overdose crisis has tarred yet another of the nation’s business titans: McKinsey, a globally renowned consulting firm, has discovered that providing corporate clients sketchy advice about addictive, debilitating, and even lethal prescription medications can have consequences.

The firm, which has apologized for its conduct, has agreed to pay $573.9 million in a settlement with 47 states over consulting work it did for multiple Big Pharma companies, notably with Purdue Pharmaceuticals, the maker of the drug OxyContin.

Critics of Purdue, citing media investigations and in civil lawsuits filed by states and local governments, have argued that Purdue pioneered aggressive and deceptive advertising, marketing, and sales practices that fueled the abuse of powerful prescription painkillers and opened the door to overdoses of those drugs, synthetic versions of them, as well as illicit narcotics.

December 20, 2020

Plutocratic Sacklers say sorry but not our fault, when taken to task in hearing

by Patrick A. Malone

A key component of the American legal system, in the criminal and civil systems, is the opportunity afforded to those most harmed to see those implicated in awful situations take responsibility for their conduct. It can be a key moment for the aggrieved to find closure and a measure of justice.

December 16, 2020

Consultants apologize for opioid hype, as pharma payments take more fire

by Patrick A. Malone

Heaps of ignominy are not in short order for parties that played sketchy roles in fostering the nation’s deadly opioid abuse and drug overdose crisis. The stain has spread now to one of corporate America’s most-favored advisors — the giant McKinsey consulting group.

The firm has issued a rare public mea culpa for its work with Purdue Pharmaceuticals, a family-run drug maker that has gained notoriety, even among Big Pharma companies, for how it hyped its powerful painkiller OxyContin. The relentless push to sell that drug, officials have asserted, provided a ghastly template for peddling opioids, triggering abuse, addiction, debilitation, and death for hundreds of thousands of Americans in recent times.

Purdue was a McKinsey client, and the consultants now are re-examining their advice to the drug maker on how to fire up OxyContin sales and whether these suggestions fell short of the firm’s own standards. The New York Times, to its credit, dug into records to detail the consultants’ unacceptable conduct, reporting:

November 10, 2020

D.C. voters join a growing push to reconsider use of hallucinogenic drugs

by Patrick A. Malone

Voters in the nation’s capital joined with peers across the country to nudge forward a further reconsideration of mind-affecting substances popularized in the Sixties but made illicit thereafter.

Support ran strong for a District of Columbia ballot initiative directing local law enforcement to make among its lowest priorities the prosecution of those who use or sell certain hallucinogenic plants and fungi — aka magic mushrooms and psilocybin, the Washington Post reported.

Those substances also appeared to be headed to legalization in an Oregon vote, which also would “decriminalize the possession of all illegal drugs,” the Wall Street Journal reported.

October 27, 2020

$8.3 billion in opioid fines but no criminal charges for execs and family owners

by Patrick A. Malone

Christmas arrived before Halloween for a notorious Big Pharma firm. Federal prosecutors effectively gave its family founders and its executives gilded skates, so they can slide away for now from major criminal charges and severe financial penalties for their part in fostering the opioid abuse and drug overdose crisis that has killed hundreds of thousands of Americans and cost the nation more than $1 trillion.

The devil is in the details in the announced settlement by the U.S. Justice Department with Purdue Pharmaceutical, the maker of the powerful painkiller OxyContin.

Federal prosecutors painted a picture of their planned deal with Purdue as an historic, $8.3 billion knock-out for a company that critics say played a major role in the opioid crisis, with the firm creating a template for hyping falsehoods about the safety and effectiveness of prescription painkillers. As the Washington Post reported, the first glance at the multibillion-dollar Purdue settlement seems tough:

October 14, 2020

Will plutocrats pay $3 billion to keep $13 billion and elude opioid charges?

by Patrick A. Malone

So, who doesn’t daydream a little about money? Maybe even big money. Just imagine a scenario where, if you could put up $3,000, you could keep $13,000, or if you forked over $30,000, and walked away with $130,000? So how great would it be if you paid $3 billion but could stuff $13 billion into your pockets?

What a deal! Of course, it depends on whose perspective you look at it from.

Federal prosecutors and a bankruptcy court may give a plutocratic family that deal, along with a hard-to-imagine get-out-of-jail free card, news organizations report.